

DEC 09 2002

Applicant : Vincent P. Stanton, Jr.
 Serial No. : 09/648,123
 Filed : August 25, 2000
 Title : GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING

Art Unit : 1655
 Examiner : C. Wilder

RECEIVED
DEC 11 2002
TECH CENTER 1600/2900

BOX AF
 Commissioner for Patents
 Washington, D.C. 20231

RECEIVED
DEC 23 2002
TECH CENTER 1600/2900

RESPONSE

In response to the action mailed May 31, 2002, please amend the application as follows:

In the claims:

Please cancel claims 17-26.

Add new claims 27-34

B1
 --27. An isolated nucleic acid probe comprising at least 15 nucleotides which hybridizes under stringent conditions to a variant human cytochrome P-450 (CYP3A4) gene having a T to C variance at nucleotide 732 and does not hybridize under stringent conditions to a human cytochrome P-450 (CYP3A4) gene not having a T to C variance at nucleotide 732.

28. The probe of claim 27 wherein the probe comprises fewer than 200 nucleotides.

29. The probe of claim 27 wherein the probe comprises fewer than 100 nucleotides.

30. The probe of claim 27 wherein the probe comprises DNA.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

December 2, 2002

Signature

Lisa G. Gray
 Typed or Printed Name of Person Signing Certificate